Walpar Nutritions Ltd
WALPAR NSE
Walpar Nutritions Ltd
HealthcareNSE: WALPAR Pharmaceuticals & Biotechnology
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹31.13 Cr
Volatility
Moderate
P/E Ratio
10.9
EBITDA
₹6.66 Cr
Return on Equity
14.52%
Debt to Equity
0.89
Book Value
₹20.13
EPS
₹1.63
52W High
₹50.6
52W Low
₹21.25
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Walpar Nutritions Ltd insights
29 extracted metrics + investor summaries across FY21–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.7% over last 3 years.
Growth Rate
Revenue Growth
9.43% ↘
Net Income Growth
11.79% ↗
Cash Flow Change
-24.11% ↘
ROE
22.53% ↗
ROCE
18.42% ↗
EBITDA Margin (Avg.)
1.44% ↗
Quarterly Results
| Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.98 | 13.98 | 12.78 | 16.52 | 18.62 | 31.14 | 31.38 | 32.53 | 39.24 | 36.49 | 42.3 |
| Expenses | 13.47 | 13.47 | 12.27 | 15.52 | 16.12 | 29.15 | 28.62 | 29.89 | 36.16 | 33.55 | 38.58 |
| Operating Profit | 0.51 | 0.51 | 0.51 | 1 | 2.5 | 1.99 | 2.76 | 2.64 | 3.08 | 2.94 | 3.72 |
| OPM % | 3.65% | 3.65% | 3.99% | 6.05% | 13.43% | 6.39% | 8.8% | 8.12% | 7.85% | 8.06% | 8.79% |
| Other Income | 0.04 | 0.04 | -0.02 | 0.05 | 0.27 | 0.06 | 0.16 | 0.31 | -0.04 | 0.13 | 0.13 |
| Interest | 0.25 | 0.25 | 0.24 | 0.44 | 0.36 | 0.33 | 0.34 | 0.26 | 0.03 | 0.3 | 0.5 |
| Depreciation | 0.13 | 0.13 | 0.15 | 0.84 | 1.07 | 0.92 | 0.89 | 0.88 | 0.94 | 1 | 1.02 |
| PBT | 0.17 | 0.17 | 0.1 | -0.23 | 1.34 | 0.8 | 1.69 | 1.81 | 2.07 | 1.77 | 2.33 |
| Tax % | 29.41% | 29.41% | -130% | 39.13% | 15.67% | 20% | 23.08% | 22.1% | 32.85% | 15.25% | 27.04% |
| Net Profit | 0.12 | 0.12 | 0.24 | -0.33 | 1.14 | 0.65 | 1.29 | 1.41 | 1.39 | 1.5 | 1.5 |
| EPS in Rs | 0.19 | 0.14 | 0.27 | -0.42 | 1.07 | 0.43 | 1.26 | 1.37 | 1.11 | 1.37 | 1.26 |
Profit & Loss
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 6.07 | 26.76 | 35.14 | 62.52 | 71.76 | 78.79 |
| Expenses | 5.61 | 25.74 | 31.65 | 57.77 | 66.04 | 72.13 |
| Operating Profit | 0.46 | 1.02 | 3.49 | 4.75 | 5.72 | 6.66 |
| OPM % | 7.58% | 3.81% | 9.93% | 7.6% | 7.97% | 8.45% |
| Other Income | 0 | 0.02 | 0.32 | 0.22 | 0.27 | 0.26 |
| Interest | 0.18 | 0.48 | 0.79 | 0.67 | 0.29 | 0.8 |
| Depreciation | 0.12 | 0.28 | 1.91 | 1.81 | 1.82 | 2.02 |
| PBT | 0.16 | 0.28 | 1.11 | 2.49 | 3.88 | 4.1 |
| Tax % | 6.25% | -32.14% | 27.03% | 22.09% | 27.84% | 21.71% |
| Net Profit | 0.15 | 0.36 | 0.81 | 1.94 | 2.79 | 3 |
| EPS in Rs | 0.22 | 0.42 | 0.65 | 1.68 | 2.47 | 2.63 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3.34 | 4.54 | 4.54 | 4.7 | 9.39 | 9.39 |
| Reserves | 1.44 | 6.45 | 7.17 | 9.49 | 7.17 | 9.51 |
| Borrowings | 7.49 | 7.25 | 10.3 | 8.3 | 7.85 | 16.77 |
| Other Liabilities | 5.73 | 9.85 | 12.29 | 14.67 | 22.98 | 30.4 |
| Total Liabilities | 18 | 28.09 | 34.3 | 37.16 | 47.39 | 66.07 |
| Fixed Assets | 1.7 | 2.01 | 10.13 | 10.2 | 10.65 | 12.21 |
| CWIP | 1.22 | 4.48 | 0.02 | 0.02 | 0.03 | 0.05 |
| Investments | 0 | 0.49 | 0.02 | 1.88 | 1.88 | 2.88 |
| Other Assets | 15.08 | 21.11 | 24.13 | 25.06 | 34.83 | 50.93 |
| Total Assets | 18 | 28.09 | 34.3 | 37.16 | 47.39 | 66.07 |
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Operating | -0.31 | -1.08 | 1.1 | 5.35 | 4.06 | 1.83 |
| Investing | -2.02 | -6.14 | -3.44 | -3.61 | -2.3 | -6.57 |
| Financing | 2.95 | 6.71 | 2.42 | -1.77 | -0.68 | 8.08 |
| Net Cash Flow | 0.62 | -0.51 | 0.07 | -0.03 | 1.08 | 3.34 |
| Free Cash Flow | -2.17 | -4.92 | -4.14 | 3.48 | 1.78 | -1.76 |
| CFO/OP | -67 | -99 | 34 | 116 | 82 | 41 |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 431 | 124 | 130 | 78.46 | 108 | 109 |
| Inventory Days | 369 | 103 | 129 | 67.15 | 67.85 | 93.74 |
| Days Payable | 455 | 135 | 144 | 72.94 | 109 | 136 |
| Cash Conversion Cycle | 344 | 92.41 | 114 | 72.67 | 67.07 | 66.06 |
| Working Capital Days | 316 | 61.65 | 87.87 | 43.55 | 42.17 | 40.67 |
| ROCE % | — | 4.85% | 8.78% | 12.75% | 16.08% | 14.84% |
Documents
1
General Updates
27 Jul - Company states corporate governance provisions are not applicable for quarter ended 30 June 2026. 27 Jul - Company states corporate governance provisions are not applicable for quarter ended 30 June 2026.
2
Structural Digital Database
21 Jul - Submitted SDD compliance certificates for quarter ended 30 June 2026, confirming no non-compliance. 21 Jul - Submitted SDD compliance certificates for quarter ended 30 June 2026, confirming no non-compliance.
3
Reply to Clarification- Financial results
14 Jul - Walpar corrected XBRL tax figure discrepancy in FY25 results; no other financial changes. 14 Jul - Walpar corrected XBRL tax figure discrepancy in FY25 results; no other financial changes.
4
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026; no physical shares received for dematerialization. 9 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026; no physical shares received for dematerialization.
5
General Updates
8 Jul - Company denies any price-sensitive event after NSE sought clarification on recent share price movement. 8 Jul - Company denies any price-sensitive event after NSE sought clarification on recent share price movement.
Frequently Asked Questions about Walpar Nutritions Ltd
What does Walpar Nutritions Ltd do?
Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products.[1]
Where is Walpar Nutritions Ltd (WALPAR) listed?
Walpar Nutritions Ltd is listed on the Indian stock exchanges. It is listed on NSE: WALPAR. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Walpar Nutritions Ltd belong to?
Walpar Nutritions Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Walpar Nutritions Ltd?
Walpar Nutritions Ltd has a market capitalisation of approximately ₹31.13 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Walpar Nutritions Ltd?
The Price-to-Earnings (PE) ratio of Walpar Nutritions Ltd is 10.90. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Walpar Nutritions Ltd?
Over the past 52 weeks, Walpar Nutritions Ltd has traded between a low of ₹21.25 and a high of ₹50.6. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Walpar Nutritions Ltd?
Walpar Nutritions Ltd has a Return on Equity (ROE) of 14.52%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Walpar Nutritions Ltd on Tapetide?
On Tapetide, you can view Walpar Nutritions Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products.[1]